Cargando…
HMG CoA reductase expression as a prognostic factor in Korean patients with breast cancer: A retrospective study
There are many preclinical and epidemiological reports suggesting a correlation between 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) or HMG-CoAR inhibitor (statin) treatment and prognosis in breast cancer. This study aimed to investigate the expression of HMG-CoAR in Korean patients wi...
Autores principales: | Kim, Hyojeong, Seol, Young Mi, Choi, Young Jin, Shin, Ho-Jin, Chung, Joo Seop, Shin, Nari, Kim, Ahrong, Kim, Jee Yeon, Kim, Keun Young, Bae, Youngtae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456116/ https://www.ncbi.nlm.nih.gov/pubmed/30921201 http://dx.doi.org/10.1097/MD.0000000000014968 |
Ejemplares similares
-
Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity
por: Hong, Joo Young, et al.
Publicado: (2017) -
Eupatilin Alleviates Hyperlipidemia in Mice by Inhibiting HMG-CoA Reductase
por: Kim, Kyung-Joo, et al.
Publicado: (2023) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023) -
Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research
por: Kim, Hun-Sung, et al.
Publicado: (2017) -
Pleiotropic effects of the HMG-CoA reductase inhibitors
por: Mihos, Christos G, et al.
Publicado: (2011)